title: Alpha-1 antitrypsin treatment of spontaneously diabetic nonobese diabetic mice receiving islet allografts.
abstract: Alpha-1 antitrypsin (AAT) is a serine protease inhibitor able to prevent diabetes onset in nonobese diabetic (NOD) mice and to prolong islet allograft survival in a nonautoimmune murine model. In this study, we explored the effect of chronic administration of human AAT (hAAT) on allogeneic (C57BL/6) islet graft survival in spontaneously diabetic female NOD mice. Mice received intraperitoneal treatment with saline, Prolastin (1 or 2 mg/mouse) or Aralast (2 mg/mouse) on days -1, 0, 3, 6, and 9. Saline-treated mice rejected the grafts 10.0 +/- 2.5 days after transplantation (n = 9). Prolastin 1 mg (n = 9) and 2 mg (n = 3) resulted in rejection on 8.7 +/- 1.4 (not significant) and 13.0 +/- 4.3 days (P < .03), respectively. Aralast-treated mice showed prolongation of graft survival (13 +/- 5.9 days; n = 5; P < .03). Notably, repeated administrations of either hAAT formulation led to sudden death of a proportion of treated animals. Collectively, our preliminary data indicate that prolongation of islet allograft survival in the stringent autoimmune diabetic NOD mouse model can be achieved with hAAT monotherapy. The death of a proportion of treated animals may be consequent to immunization to hAAT and lethal hypersensitivity. Interestingly, this phenomenon was not observed in a non-autoimmune mouse strain (C57BL/6) despite extended hAAT treatment (>100 days).
authors: JDRFI Gene Therapy Center for the Prevention of Diabetes and Diabetic Complications at the University of Florida, Florida, USA.
authors: A
authors: A
authors: Pileggi
authors: R D
authors: RD
authors: Molano
authors: S
authors: S
authors: Song
authors: E
authors: E
authors: Zahr
authors: S
authors: S
authors: SanJose
authors: S
authors: S
authors: Villate
authors: C
authors: C
authors: Wasserfall
authors: C
authors: C
authors: Ricordi
authors: M A
authors: MA
authors: Atkinson
authors: L
authors: L
authors: Inverardi
mesh_terms: D000818:Animals; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*
chemical_list: D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin